Seeking Alpha
 

Baxter International Inc (BAX)

- NYSE
  • May. 7, 2013, 8:25 AM
    Baxter International (BAX) slips 2.2% premarket after Phase III testing on its Alzheimer's drug immunoglobulin (IG) - always a long shot - failed to meet its co-primary endpoints. (PR)
    | 1 Comment
  • May. 7, 2013, 6:21 AM
    Baxter International (BAX) declares $0.49/share quarterly dividend, 9% increase from prior dividend of $0.45. Forward yield 2.56%. For shareholders of record June 07. Payable July 01. Ex-div date June 05. (PR)
    | Comment!
  • May. 6, 2013, 7:02 AM
    Vical (VICL) says the addition of its Vaxfectin adjuvant to Baxter's (BAX) influenza vaccines "substantially increases both antibody and T-cell responses." VICL's VP of vaccine research says seasonal influenza vaccines sometimes underperform in elderly patients — "a good adjuvant could" help, he adds. (PR)
    | Comment!
  • Apr. 26, 2013, 3:42 PM
    Looking for dividend picks, Marketwatch screens the S&P 1,500 for 1) Stock trades at less than a 17x PE 2) Dividend yield 20% or more higher than S&P 500 3) Raised dividend at least 5 times in last 5 years 4) S&P Quality Rank of B+ or better. The winners: T, AVA, BAX, CAH, CAG, ED, JNJ, LG, TAP, RAI, SCG, UVV, WR, XEL.
    | 1 Comment
  • Apr. 18, 2013, 9:03 AM
    More on Baxter (BAX) Q1: net profit -11% to $552M, dragged down by charges related to its purchase of Gambrro, while last year's figures included a tax benefit. Medical-products sales -0.4% to $1.92B, BioScience revenue +4.7% to $1.53B. Expects sales growth of 4% in Q2 and 10% for FY; forecasts EPS of Q2 EPS of $1.12-1.14 vs consensus of $1.14 and 2014 EPS of $4.60-4.70 vs 4.66. (PR)
    | Comment!
  • Apr. 18, 2013, 7:03 AM
    Baxter (BAX): Q1 EPS of $1.05 in-line. Revenue of $3.45B (+2% Y/Y) misses by $0.04B. (PR)
    | Comment!
  • Apr. 18, 2013, 12:05 AM
    Notable earnings before Thursday’s open: ADS, AN, APH, BAX, BBT, BPOP, BTU, BX, CY, DHR, FCS, FCX, FITB, KEY, LDK, MMR, MS, NOK, NUE, OMC, PBCT, PENN, PEP, PM, PPG, SHW, SNA, SON, TSM, TZOO, UNH, UNP, VZ
    | Comment!
  • Apr. 17, 2013, 5:30 PM
    Notable earnings before Thursday’s open: ADS, AN, APH, BAX, BBT, BPOP, BTU, BX, CY, DHR, FCS, FCX, FITB, KEY, LDK, MMR, MS, NOK, NUE, OMC, PBCT, PENN, PEP, PM, PPG, SHW, SNA, SON, TSM, TZOO, UNH, UNP, VZ
    | Comment!
  • Apr. 4, 2013, 4:45 AM
    The cost of caring for people with dementia is $157-215B a year and could double by 2040, a study from RAND Corp. estimates. The cost of dementia treatment is $109B - above the $102B spent on heart disease and the $77B on cancer - with the other dementia expenses used for long-term day-to-day care. Companies that develop drugs for Alzheimer's disease and other conditions include Pfizer (PFE), Eli Lilly (LLY), J&J (JNJ) and Merck (MRK).
    | 5 Comments
  • Mar. 22, 2013, 9:29 AM
    Halozyme Therapeutics (HALO) +18.6% premarket after the European Medicines Agency approves partner Baxter (BAX) for the use of HALO's HyQvia as replacement therapy for adult patients with primary and secondary immunodeficiencies. Upon receiving marketing authorization from the EC, BAX plans to launch HyQvia in some European countries later this year.
    | Comment!
  • Feb. 19, 2013, 9:35 AM
    Baxter International Inc. (BAX) declares $0.45/share quarterly dividend, in line with previous. Forward yield 2.64%. For shareholders of record Mar. 08. Payable Apr. 01. Ex-div date Mar. 06. (PR)
    | Comment!
  • Jan. 24, 2013, 9:14 AM
    More on Baxter's (BAXQ4 results: Forecasts current-quarter EPS of $1.03-$1.05 on 2%-3% sales growth vs. consensus of $1.10 on 4% revenue growth to $3.5B. Forecasts 2013 EPS of $4.60-$4.70 on 10% sales growth vs. consensus $4.84 on 5% revenue growth of $14.8B. Acquires investigational hemophilia compound OBI-1 and related assets from Inspiration BioPharmaceuticals.
    | Comment!
  • Jan. 24, 2013, 7:03 AM
    Baxter (BAX): Q4 EPS of $1.26 in-line. Revenue of $3.8B (+4% Y/Y) beats by $0.08B. (PR)
    | Comment!
  • Jan. 24, 2013, 12:05 AM
    Notable earnings before Thursday’s open: ABC, ALK, ARG, AVT, BAX, BMY, BPOP, CELG, CY, DOV, EQT, ESI, ETN, FCS, GWW, JNS, JVA, KCG, KEY, LMT, LUV, MKC, MMM, MWW, NMM, NOK, ORI, PCP, QSII, RTN, RYN, SWK, TZOO, UAL, UNP, XRX
    | Comment!
  • Jan. 23, 2013, 5:30 PM
    Notable earnings before Thursday’s open: ABC, ALK, ARG, AVT, BAX, BMY, BPOP, CELG, CY, DOV, EQT, ESI, ETN, FCS, GWW, JNS, JVA, KCG, KEY, LMT, LUV, MKC, MMM, MWW, NMM, NOK, ORI, PCP, QSII, RTN, RYN, SWK, TZOO, UAL, UNP, XRX
    | Comment!
  • Dec. 4, 2012, 9:07 AM
    More on Baxter (BAX) / Gambro deal: the acquisition, Baxter's largest ever, combines the second and third largest manufacturers of dialysis equipment, so it could arouse antitrust concerns. Baxter expects synergies of $300M a year by 2017, but says the deal will cut adjusted EPS by $0.10-$0.15 next year and be neutral or add to earnings in 2014, and then add to profit after that. (Webcast) (PR)
    | Comment!
BAX vs. ETF Alternatives
Company Description
Baxter International Inc is a healthcare company which develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic.